Publications by authors named "J M Fris"
Background: There is a need to expand eligibility criteria for lung cancer screening beyond age and smoking history. In this study, we sought to assess whether light-or-never-smokers and heavy smokers differ in molecular and immunologic markers based on conventional lung cancer screening criteria.
Methods: We conducted a retrospective review of lung cancer cases from 2005 to 2018 at a tertiary Canadian institution.
Article Synopsis
- This study examines the differences in PD-L1 scores between fresh and archived tissue samples from lung cancer patients, highlighting significant variability over a six-month period.
- The results indicate that advanced cancer stages show increased PD-L1 expression, with implications for survival rates depending on the presence of driver mutations.
- The findings suggest that PD-L1 scores can influence treatment outcomes, particularly with immunotherapy, indicating a need for careful assessment of tissue samples in clinical decision-making.
Screening Criteria Evaluation for Expansion in Pulmonary Neoplasias (SCREEN).
Semin Thorac Cardiovasc Surg
November 2023
The SCREEN study investigated screening eligibility and survival outcomes between heavy smokers and light-or-never-smokers with lung cancer to determine whether expanded risk factor analysis is needed to refine screening criteria. SCREEN is a retrospective study of 917 lung cancer patients diagnosed between 2005 and 2018 in Nova Scotia, Canada. Screening eligibility was determined using the National Lung Screening Trial (NSLT) criteria.
View Article and Find Full Text PDFMost lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with very low response rate. Lung cancer is the most common cause of cancer death worldwide. Therapies that target driver gene mutations (e.
View Article and Find Full Text PDF